Background Azithromycin is a macrolide antibiotic with anti-inflammatory and
immunomodulatory properties. We tested the hypothesis that azithromycin would decrease …

Importance Macrolide antibiotics have been shown beneficial in cystic fibrosis (CF) and
diffuse panbronchiolitis, and earlier findings also suggest a benefit in non-CF …

We describe our institutional efficacy experience of azithromycin 250mg thrice weekly in
adult non-cystic fibrosis bronchiectasis. METHODS: Eligibility criteria for prophylactic …

Introduction Bronchiectasis is a chronic pulmonary process characterized by recurrent
respiratory infections leading to destruction of airways secondary to inflammation. We …

Background Indigenous children in high-income countries have a heavy burden of
bronchiectasis unrelated to cystic fibrosis. We aimed to establish whether long-term …

Background The clinical benefit of inhaled antibiotics in non-cystic fibrosis bronchiectasis
has not been established in randomised controlled trials. We aimed to assess safety and …

Importance Macrolide antibiotics such as erythromycin may improve clinical outcomes in
non–cystic fibrosis (CF) bronchiectasis, although associated risks of macrolide resistance …

Background Although amoxicillin–clavulanate is the recommended first-line empirical oral
antibiotic treatment for non-severe exacerbations in children with bronchiectasis …

Background Bronchiectasis guidelines recommend long-term macrolide treatment for
patients with three or more exacerbations per year without Pseudomonas aeruginosa …

We conducted a meta-analysis of randomised trials to evaluate the efficacy and safety of
inhaled antibiotics in patients with stable non-cystic fibrosis (CF) bronchiectasis. We …